Pfizer-BioNTech to develop mRNA-based shingles shot

AFP

3 min read
Syringes and vials of the Pfizer-BioNTech vaccine against the coronavirus are pictured at a private nursing home in the Israeli central coastal city of Netanya on January 5, 2022.
JACK GUEZ / AFPSyringes and vials of the Pfizer-BioNTech vaccine against the coronavirus are pictured at a private nursing home in the Israeli central coastal city of Netanya on January 5, 2022.

Moderna announces start of clinical trial for mRNA vaccine against Epstein-Barr virus

Germany's BioNTech and US pharma giant Pfizer, which together developed a Covid-19 vaccine in record time, said Wednesday they are working on a shingles shot using the same mRNA technology.

Moderna meanwhile announced it had dosed its first volunteer for a vaccine against Epstein-Barr virus (EBV), the cause of mononucleosis.

The three companies are leveraging the same mRNA technology they used to develop highly successful Covid-19 vaccines towards other diseases, in a potential breakthrough moment for modern medicine.

Pfizer and BioNTech signed a partnership deal and are aiming for clinical trials to start in the second half of 2022, they said in a joint statement.

https://twitter.com/i/web/status/1478703843089260547 ...

This post can't be displayed because social networks cookies have been deactivated. You can activate them by clicking .

"The collaboration aims to develop a new mRNA-based vaccine against shingles, leveraging the expertise and resources of both companies," said Ugur Sahin, CEO and co-founder of BioNTech.

The messenger RNA method made its debut with the Pfizer-BioNTech coronavirus vaccine, which was the first jab against Covid to be approved in the West in late 2020.

Shingles is a common disease around the world caused by reactivation of the same virus that causes chickenpox.

Video poster

It can lead to extremely painful, disfiguring skin patches, and in rare cases to facial paralysis, deafness and blindness.

While there are currently approved vaccines for shingles, Pfizer and BioNTech said they wanted to develop an improved vaccine that potentially shows high efficacy and better tolerability.

The coronavirus jab developed by US biotech Moderna together with the US government agency National Institutes of Health (NIH) also uses mRNA technology.